Research ArticleOriginal Article

Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study

Dongming Liu, Yi Luo, Lu Chen, Liwei Chen, Duo Zuo, Yueguo Li, Xiaofang Zhang, Jing Wu, Qing Xi, Guangtao Li, Lisha Qi, Xiaofen Yue, Xiehua Zhang, Zhuoyu Sun, Ning Zhang, Tianqiang Song, Wei Lu and Hua Guo
Cancer Biology & Medicine February 2021, 18 (1) 256-270; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0207

References

  1. 1.↵
    2. Torre LA,
    3. Bray F,
    4. Siegel RL,
    5. Ferlay J,
    6. Lortet-Tieulent J,
    7. Jemal A.
    Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87–108.
    OpenUrlCrossRefPubMed
  2. 2.
    2. Bray F,
    3. Ferlay J,
    4. Soerjomataram I,
    5. Siegel RL,
    6. Torre LA,
    7. Jemal A.
    Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–424.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Chen L,
    3. Liu D,
    4. Yi X,
    5. Qi L,
    6. Tian X,
    7. Sun B, et al.
    The novel miR-1269b-regulated protein SVEP1 induces hepatocellular carcinoma proliferation and metastasis likely through the PI3K/Akt pathway. Cell Death Dis. 2020; 11: 320.
    OpenUrl
  4. 4.↵
    2. Forner A,
    3. Reig M,
    4. Bruix J.
    Hepatocellular carcinoma. Lancet. 2018; 391: 1301–14.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Chen L,
    3. Yi X,
    4. Guo P,
    5. Guo H,
    6. Chen Z,
    7. Hou C, et al.
    The role of bone marrow-derived cells in the origin of liver cancer revealed by single-cell sequencing. Cancer Biol Med. 2020; 17: 142–53.
    OpenUrl
  6. 6.↵
    2. Dhir M,
    3. Melin AA,
    4. Douaiher J,
    5. Lin C,
    6. Zhen WK,
    7. Hussain SM, et al.
    A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg. 2016; 263: 1112–25.
    OpenUrl
  7. 7.↵
    2. Chen L,
    3. Guo P,
    4. He Y,
    5. Chen Z,
    6. Chen L,
    7. Luo Y, et al.
    HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway. Cell Death Dis. 2018; 9: 513.
    OpenUrlCrossRef
  8. 8.↵
    2. Utsunomiya T,
    3. Shimada M,
    4. Kudo M,
    5. Ichida T,
    6. Matsui O,
    7. Izumi N, et al.
    Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. Ann Surg. 2014; 259: 336–45.
    OpenUrlPubMed
  9. 9.↵
    2. Mali P,
    3. Yang L,
    4. Esvelt KM,
    5. Aach J,
    6. Guell M,
    7. DiCarlo JE, et al.
    RNA-guided human genome engineering via Cas9. Science. 2013; 339: 823–6.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Martinez MG,
    3. Testoni B,
    4. Zoulim F.
    Biological basis for functional cure of chronic hepatitis B. J Viral Hepat. 2019; 26: 786–94.
    OpenUrl
  11. 11.↵
    2. Utsunomiya T,
    3. Shimada M,
    4. Kudo M,
    5. Ichida T,
    6. Matsui O,
    7. Izumi N, et al.
    A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg. 2015; 261: 513–20.
    OpenUrlCrossRef
  12. 12.↵
    2. Shen Q,
    3. Fan J,
    4. Yang XR,
    5. Tan Y,
    6. Zhao W,
    7. Xu Y, et al.
    Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012; 13: 817–26.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    2. Johnson PJ.
    The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001; 5: 145–59.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Jung KS,
    3. Kim SU,
    4. Song K,
    5. Park JY,
    6. Kim DY,
    7. Ahn SH, et al.
    Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology. 2015; 62: 1757–66.
    OpenUrlPubMed
  15. 15.↵
    2. Zhou J,
    3. Yu L,
    4. Gao X,
    5. Hu J,
    6. Wang J,
    7. Dai Z, et al.
    Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011; 29: 4781–8.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Yang T,
    3. Xing H,
    4. Wang G,
    5. Wang N,
    6. Liu M,
    7. Yan C, et al.
    A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin Chem. 2019; 65: 1543–53.
    OpenUrlAbstract/FREE Full Text
  17. 17.
    2. Kim DJ,
    3. Cho EJ,
    4. Yu KS,
    5. Jang IJ,
    6. Yoon JH,
    7. Park T, et al.
    Comprehensive metabolomic search for biomarkers to differentiate early stage hepatocellular carcinoma from cirrhosis. Cancers (Basel). 2019; 11: 1497.
    OpenUrl
  18. 18.↵
    2. Ye X,
    3. Li C,
    4. Zu X,
    5. Lin M,
    6. Liu Q,
    7. Liu J, et al.
    A large-scale multicenter study validates Aldo-Keto reductase family 1 member B10 as a prevalent serum marker for detection of hepatocellular carcinoma. Hepatology. 2019; 69: 2489–501.
    OpenUrl
  19. 19.↵
    2. Cui R,
    3. He J,
    4. Zhang F,
    5. Wang B,
    6. Ding H,
    7. Shen H, et al.
    Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer. 2003; 88: 1878–82.
    OpenUrlCrossRefPubMed
  20. 20.
    2. Miyahara K,
    3. Nouso K,
    4. Tomoda T,
    5. Kobayashi S,
    6. Hagihara H,
    7. Kuwaki K, et al.
    Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2011; 26: 1604–11.
    OpenUrlCrossRefPubMed
  21. 21.↵
    2. Wang K,
    3. Guo W,
    4. Li N,
    5. Shi J,
    6. Zhang C,
    7. Lau WY, et al.
    Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study. Br J Cancer. 2014; 110: 1811–9.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Zhou F,
    3. Shang W,
    4. Yu X,
    5. Tian J.
    Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018; 38: 741–67.
    OpenUrlCrossRef
  23. 23.↵
    2. Waidely E,
    3. Al-Yuobi AR,
    4. Bashammakh AS,
    5. El-Shahawi MS,
    6. Leblanc RM.
    Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst. 2016; 141: 36–44.
    OpenUrl
  24. 24.↵
    2. Xing H,
    3. Qiu H,
    4. Ding X,
    5. Han J,
    6. Li Z,
    7. Wu H, et al.
    Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma. Biomark Med. 2019; 13: 545–55.
    OpenUrl
  25. 25.↵
    2. Yao M,
    3. Yao DF,
    4. Bian YZ,
    5. Wu W,
    6. Yan XD,
    7. Yu DD, et al.
    Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013; 12: 171–9.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. El-Saadany S,
    3. El-Demerdash T,
    4. Helmy A,
    5. Mayah WW,
    6. El-Sayed Hussein B,
    7. Hassanien M, et al.
    Diagnostic value of glypican-3 for hepatocellular carcinomas. Asian Pac J Cancer Prev. 2018; 19: 811–7.
    OpenUrl
  27. 27.↵
    2. Zhao S,
    3. Long M,
    4. Zhang X,
    5. Lei S,
    6. Dou W,
    7. Hu J, et al.
    The diagnostic value of the combination of Golgi protein 73, glypican-3 and alpha-fetoprotein in hepatocellular carcinoma: a diagnostic meta-analysis. Ann Transl Med. 2020; 8: 536.
    OpenUrl
  28. 28.↵
    2. Xu KC,
    3. Meng XY,
    4. Shi YC,
    5. Ge ZJ,
    6. Ye L,
    7. Yu ZJ, et al.
    The diagnostic value of a hepatoma-specific band of serum gamma-glutamyl transferase. Int J Cancer. 1985; 36: 667–9.
    OpenUrlPubMed
  29. 29.↵
    2. Rimassa L,
    3. Assenat E,
    4. Peck-Radosavljevic M,
    5. Pracht M,
    6. Zagonel V,
    7. Mathurin P, et al.
    Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018; 19: 682–93.
    OpenUrlPubMed
  30. 30.↵
    2. Kim HY,
    3. Lee DH,
    4. Lee JH,
    5. Cho YY,
    6. Cho EJ,
    7. Yu SJ, et al.
    Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer. 2018; 18: 307.
    OpenUrl
  31. 31.↵
    2. Liu D,
    3. Lin L,
    4. Wang Y,
    5. Chen L,
    6. He Y,
    7. Luo Y, et al.
    PNO1, which is negatively regulated by miR-340-5p, promotes lung adenocarcinoma progression through Notch signaling pathway. Oncogenesis. 2020; 9: 58.
    OpenUrl
  32. 32.↵
    2. Li T,
    3. Qin LX,
    4. Gong X,
    5. Zhou J,
    6. Sun HC,
    7. Qiu SJ, et al.
    Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer. 2013; 119: 126–35.
    OpenUrlPubMed
  33. 33.↵
    2. Sasaki Y,
    3. Yamada T,
    4. Tanaka H,
    5. Ohigashi H,
    6. Eguchi H,
    7. Yano M, et al.
    Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg. 2006; 244: 771–80.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    2. Chen W,
    3. Zheng R,
    4. Baade PD,
    5. Zhang S,
    6. Zeng H,
    7. Bray F, et al.
    Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115–32.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Yokoi Y,
    3. Suzuki S,
    4. Baba S,
    5. Inaba K,
    6. Konno H,
    7. Nakamura S.
    Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection. J Gastroenterol. 2005; 40: 274–82.
    OpenUrlPubMed
  36. 36.↵
    2. Bertino G,
    3. Ardiri A,
    4. Malaguarnera M,
    5. Malaguarnera G,
    6. Bertino N,
    7. Calvagno GS.
    Hepatocellular carcinoma serum markers. Semin Oncol. 2012; 39: 410–33.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Chen B,
    3. Ning M,
    4. Yang G.
    Effect of paeonol on antioxidant and immune regulatory activity in hepatocellular carcinoma rats. Molecules. 2012; 17: 4672–83.
    OpenUrlPubMed
  38. 38.↵
    2. Chen Z,
    3. Ren X,
    4. Meng X,
    5. Zhang Y,
    6. Chen D,
    7. Tang F.
    Novel fluorescence method for detection of α-L-fucosidase based on CdTe quantum dots. Anal Chem. 2012; 84: 4077–82.
    OpenUrlPubMed
  39. 39.↵
    2. Zhang SY,
    3. Lin BD,
    4. Li BR.
    Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma. FEBS Open Bio. 2015; 5: 240–4.
    OpenUrl
  40. 40.↵
    2. Junna Z,
    3. Gongde C,
    4. Jinying X,
    5. Xiu Z.
    Serum AFU, 5′-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis. Open Med (Wars). 2017; 12: 354–8.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords